#134 – ESCMID Global Trials: PETER PEN and ASTARTE

About this episode

This episode discusses two randomized clinical trials on the treatment of cephalosporin-resistant Enterobacterales bacteremia presented at ESCMID Global.

Professor Mical Paul and Professor Jesús Rodríguez-Baño join Professor Josh Davis and Dr Erin McCreary for a special Breakpoints and Communicable podcast collaboration. This episode discusses the ‘Trials Run’ session at ESCMID Global, where two randomized, clinical trials are presented in great depth. This year, both trials focused on treatment of cephalosporin-resistant Enterobacterales bacteremia. Listen to the authors describe why they performed these trials, results, and implications for clinical practice. References: 1. Paul, M., & Rodríguez-Baño, J. (2026, April 20). The trial run: treatment of ESBL bacteraemia [LW1] - off to never-never land . [Presentation]. ESCMID Global 2026, Munich, Germany. ESCMID Global Virtual Platform . 2. Bitterman R, Koppel F, Mussini C, et al. Piperacillin-tazobactam versus meropenem for treatment of bloodstream infections caused by third-generation cephalosporin-resistant Enterobacteriaceae: a study protocol for a non-inferiority open-label randomised controlled trial (PeterPen). BMJ Open . 2021;11(2):e040210. Published 2021 Feb 8. doi:10.1136/bmjopen-2020-040210 3. Marín-Candón A, Rosso-Fernández CM, Bustos de Godoy N, et al. Temocillin…

People in this episode

Hosts: Josh Davis, Erin McCreary

Guests: Mical Paul, Jesús Rodríguez-Baño

Topics covered

• clinical trials
• cephalosporin-resistant Enterobacterales
• bacteremia treatment
• ESCMID Global
• infectious diseases
• pharmacology

Keywords

• clinical trials
• bacteremia
• cephalosporin resistance
• ESCMID Global
• infectious diseases
• pharmacology
• PeterPen
• ASTARTÉ

Mentioned in this episode

Organizations: ESCMID

Books & works: Piperacillin-tazobactam versus meropenem for treatment of bloodstream infections caused by third-generation cephalosporin-resistant Enterobacteriaceae: a study protocol for a non-inferiority open-label randomised controlled trial (PeterPen), Temocillin versus meropenem for the targeted treatment of bacteraemia due to third-generation cephalosporin-resistant Enterobacterales (ASTARTÉ): protocol for a randomised, pragmatic trial

More episodes of Breakpoints

• #136 – GAS, Streptococcus pyogenes: Call It What You Want, It’s Got a Big Reputation · June 5, 2026 · 1h 25m
• #135 – Stewie Struggles: Small Hospital Edition · May 22, 2026 · 1h 3m
• #133 – Trash talk: Earth Day Special on Healthcare Sustainability and Stewardship · April 17, 2026 · 48 min
• #132 – Complicated UTIs: What’s Crystal Clear & What’s Still Cloudy · March 13, 2026 · 1h 9m
• #131 – Drawing the Line: The Writing, Reach, and Limits of Guidelines · February 22, 2026 · 1h 0m
• #130 – Dosing Consult: Amoxicillin · January 30, 2026 · 1h 0m